Advanced

Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly : awareness warranted for 2017/18 season

, ; Rondy, Marc; Gherasim, Alin; Casado, Itziar; Launay, Odile; Rizzo, Caterina; Pitigoi, Daniela; Mickiene, Aukse; Marbus, Sierk D and Machado, Ausenda, et al. (2017) In Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 22(41).
Abstract

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.

Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adolescent, Adult, Aged, European Union, Female, Hospitalization/statistics & numerical data, Hospitals, Humans, Influenza A Virus, H3N2 Subtype/immunology, Influenza Vaccines/immunology, Influenza, Human/epidemiology, Male, Middle Aged, Outcome Assessment (Health Care), Seasons
in
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
volume
22
issue
41
publisher
European Centre for Disease Prevention and Control (ECDC)
external identifiers
  • scopus:85031997178
ISSN
1560-7917
DOI
10.2807/1560-7917.ES.2017.22.41.17-00645
language
English
LU publication?
yes
id
0a50a0fd-8f00-4bc6-bc77-17fd8ce06b8d
date added to LUP
2019-04-23 10:10:28
date last changed
2019-07-09 04:43:39
@article{0a50a0fd-8f00-4bc6-bc77-17fd8ce06b8d,
  abstract     = {<p>In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.</p>},
  author       = {,  and Rondy, Marc and Gherasim, Alin and Casado, Itziar and Launay, Odile and Rizzo, Caterina and Pitigoi, Daniela and Mickiene, Aukse and Marbus, Sierk D and Machado, Ausenda and Syrjänen, Ritva K and Pem-Novose, Iva and Horváth, Judith Krisztina and Larrauri, Amparo and Castilla, Jesús and Vanhems, Philippe and Alfonsi, Valeria and Ivanciuc, Alina E and Kuliese, Monika and van Gageldonk-Lafeber, Rianne and Gomez, Veronica and Ikonen, Niina and Lovric, Zvjezdana and Ferenczi, Annamária and Moren, Alain},
  issn         = {1560-7917},
  keyword      = {Adolescent,Adult,Aged,European Union,Female,Hospitalization/statistics & numerical data,Hospitals,Humans,Influenza A Virus, H3N2 Subtype/immunology,Influenza Vaccines/immunology,Influenza, Human/epidemiology,Male,Middle Aged,Outcome Assessment (Health Care),Seasons},
  language     = {eng},
  number       = {41},
  publisher    = {European Centre for Disease Prevention and Control (ECDC)},
  series       = {Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin},
  title        = {Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly : awareness warranted for 2017/18 season},
  url          = {http://dx.doi.org/10.2807/1560-7917.ES.2017.22.41.17-00645},
  volume       = {22},
  year         = {2017},
}